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Synopsis 
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy. T-
PLL can be distinguished from other lymphoid diseases by the evaluation and 
integration of clinical features, morphology, immunophenotyping, cytogenetics and 
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molecular features.  The current therapeutic approach relies upon immunotherapy 
followed by a hematopoietic stem cell transplant (HSCT) in selected cases. Clinical 
outcomes are generally poor, although insights from genomic and molecular studies 
may increase our understanding of this disease, with the promise of additional effective 
therapeutic options. 
 
Key Points: 
 T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive leukemia. 
 The current therapeutic approach utilizes immunotherapy followed by a 
hematopoietic stem cell transplant (HSCT) in eligible cases. 
 Genomic and molecular studies may increase our understanding of this disease, 
with the promise of novel therapeutic options. 
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INTRODUCTION 
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy first 
described by Catovsky et al over 40 years ago.1 Although termed ‘prolymphocytic’, the 
disease is characterized by the proliferation of post-thymic T-lymphocytes.  T-PLL can 
be distinguished from other lymphoid diseases by the evaluation and integration of 
clinical features, morphology, immunophenotyping, cytogenetics and molecular 
features.  The current therapeutic approach relies upon immunotherapy followed by a 
hematopoietic stem cell transplant (HSCT) in selected cases. Clinical outcomes are 
generally poor, although insights from genomic and molecular studies may increase our 
understanding of this disease, with the promise of additional effective therapeutic 
options. 
 
EPIDEMIOLOGY 
T-PLL accounts for 2% of mature lymphocytic leukemia in adults.2 The median age at 
presentation is 61 years of age and there is a male predominance.3 Three cases of 
children with T-PLL have been reported, although incomplete diagnostics were 
reported in one.4-6 Patients with ataxia telangiectasia are at increased risk of developing 
T-PLL (as well as other lymphoid malignancies) with a younger median age at 
presentation of approximately 31 years of age.7 An individual with Nijmegen breakage 
syndrome developing T-PLL has been reported.8 Aside from these findings, no other 
genetic or environmental risk factor has been robustly identified thus far. 
 
CLINICAL FEATURES 
Most patients with T-PLL present with a brief history of B symptoms, 
hepatosplenomegaly (splenomegaly is often massive) and a marked lymphocytosis 
  Sud et al 
 
 4 
(typically >100x109/l).3  Lymphadenopathy, although present in a majority of patients, 
is rarely bulky. Anemia and thrombocytopenia are seen in up to half of patients.3  
Erythematous or nodular skin rashes involving the trunk or limbs, peripheral edema 
and pleuro-peritoneal effusions may be seen in up to a quarter of patients with T-PLL.9 
T-PLL may also involve the face, where it manifests as purpura and edema, often in a 
periorbital distribution.10,11 Central nervous system (CNS) involvement is rare. A 
minority of patients have no symptoms at diagnosis.  This ‘indolent’ phase can persist 
for a variable length of time, and can be as long as years. Disease progression may be 
rapid when it occurs. 
 
LABORATORY DIAGNOSIS 
The diagnosis of T-PLL relies on an integrated evaluation of clinical features, peripheral 
blood, morphology, immunophenotyping, bone marrow, cytogenetics and molecular 
tests.   
 
Morphology 
The ‘typical’ morphology observed in 75 percent of cases consists of medium sized 
lymphoid cells with partial chromatin condensation, a visible nucleolus and a round or 
oval nucleus (Figure 1).2,9   A slight basophilic cytoplasm is present, often with 
protrusions and an absence of granules.  A ‘small cell variant’ is seen in 20% of cases. 
These small cells possess condensed chromatin with a small nucleolus (observed only 
by electron microscopy).  Finally, the ‘cerebriform (Sézary cell-like) variant’ is seen in 
5% of patients in which the morphology resembles the Sézary cells seen in Sézary 
syndrome (SS)/mycosis fungoides (MF). The bone marrow is infiltrated in an interstitial 
pattern by cells with a similar morphology to that seen in the peripheral blood. Skin 
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biopsy of affected areas demonstrates a wide cyto-morphological spectrum similar to 
that observed in the peripheral blood with a perivascular or diffuse dermal infiltrate, 
sometimes with accompanying haemorrhage.10,11 These findings are distinct from MF in 
which atypical small to medium sized T-cells (with characteristic ‘cerebriform’ nuclei), 
infiltrate the epidermis and upper dermis, form Pautrier microabscesses with 
Langerhans cells, and accumulate along the basal layer of the epidermis (termed ‘string 
of pearls’).12 The spleen demonstrates an atrophied white pulp with dense lymphoid 
infiltrates in the red pulp that invade the capsule. Lymph node involvement is diffuse, 
often with prominent high-endothelial venules.  
 
Immunophenotype 
Flow cytometry confirms a post-thymic T-cell population (TDT-, CD1A-, CD5+, CD2+, 
CD7+).2 The majority of cases are CD4+/CD8-. Dual CD4+/CD8+ cells occur in 
approximately 25% of cases (this is unique to the post-thymic T-cell malignancies) and 
only a minority of cases express a CD4-/CD8+ phenotype. CD52 is expressed strongly.  
Cytoplasmic CD3 is always present, but membrane expression may be weak or negative. 
NK and cytoplasmic granule markers are consistently negative. Typically CD7 
expression is strong, whilst CD25 may be negative, thus helping to distinguish T-PLL 
from adult T-cell leukemia (ATL) and SS. T-PLL patients are also negative for human T-
cell leukemia virus type 1 (HTLV-1). 
 
Molecular genetics 
T-cell receptor genes are rearranged and are identical, confirming a clonal expansion of 
T-cells.  Although cytogenetic and mutational analysis does not alter management, the 
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identification of abnormalities can aid diagnosis as well as provide insight into the 
pathogenesis of T-PLL. 
The most frequently observed group of cytogenetic abnormalities involve chromosome 
14 (90%). These may take the form of inv(14), t(14;14)(q11;q32) which involve the 
TCL1A and TCL1B locus and t(X;14)(q28;q11) involving a homolog of TCL1, MTCP1 
(mature T cell proliferation 1 gene), which is located on the X-chromosome.13 
Transgenic mouse models have confirmed the oncogenic roles of TCL1 and MTCP1,14,15 
and functional work identifies TCL1 as an Akt kinase coactivator, promoting cell 
survival and proliferation.16 Cytogenetic abnormalities involving chromosome 8 are the 
next most frequently observed (idic(8p11), t(8;8) and trisomy 8q).17,18 Other recurrent 
abnormalities seen with conventional techniques include loss of 11q23 (ATM 
inactivation) together with additional losses (22q, 13q, 6q, 9p, 12p, 17p) and gains (22q 
and 6p).17,18 12p13 deletion, which probably occurs in up to half of T-PLL cases, is 
thought to contribute to the pathogenesis of T-PLL by causing haploinsufficiency of 
CDKN1B.19 With the advent of high-throughput sequencing, additional mutations in T-
PLL have been identified. These include highly recurrent, largely exclusive, gain-of-
function mutations involving IL2RG, JAK1/3, and STAT5B, which lead to constitutive 
STAT5 signaling (Figure 2)20-22. Deleterious mutations in EZH2, FBXW10 and CHEK2 
may further contribute to the pathogenesis of T-PLL through their roles in DNA repair, 
epigenetic transcriptional regulation and proteasome degradation pathways.20 Further 
genomic analysis including sequential tumor sequencing may define driver mutations 
and also the clonal architecture of T-PLL. Understanding the functional consequence of 
these mutations is essential in furthering our understanding of T-PLL and developing 
novel therapeutics.20 
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TREATMENT 
Due to the rarity of T-PLL, little published data exists regarding treatment.  No 
randomized clinical trials have been conducted.  The following recommendations are 
based on best available evidence and personal experience. 
 
Watch and wait 
Not all patients diagnosed with T-PLL require treatment immediately.  Chemo-
immunotherapy can be associated with significant toxicity and, aside from HSCT, 
current chemo-immunotherapy regimens in T-PLL are not curative.  Furthermore, some 
patients present with an ‘indolent phase’ of the disease.  Although disease progression 
eventually occurs, patients can be monitored for years before requiring intervention.  
Close monitoring (for example, blood count and clinical examination at regular 
intervals) is required as disease progression can be rapid and fatal.   A pre-treatment 
lymphocyte doubling time (LDT) of less than 8.5 months has been shown to be 
associated with a worse outcome, 23 although an absolute lymphocyte count with LDT 
should be taken into consideration when deciding upon treatment initiation. Indications 
for treatment include B symptoms, symptomatic anemia or thrombocytopenia, disease 
infiltration in the skin, lungs or CNS, and progressive disease demonstrated by an 
increasing lymphocytosis or rapidly enlarging spleen, liver or lymph nodes. 
 
First line therapy 
Treatment is initiated with the aim of attaining a complete response (CR) and patients 
should be offered a clinical trial when available.  There is a limited response to 
conventional treatment regimens such as alkylating agents or anthracyclines, with a 
median overall survival (OS) of 7 months in historical series.3 In the absence of a clinical 
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trial, patients should be offered an alemtuzumab (anti-CD52) – regimen.  This was 
initially employed over 2 decades ago and was first used due to the strong CD52 
expression on treatment-naïve T-PLL cells.  Studies suggest an overall response rate 
(ORR) of >80% in the first-line setting and in 50-76% of relapsed-refractory cases 
(Table 1).24-27 Although progression-free survival (PFS) is longer when compared to 
other therapies (over a year in responders), relapse invariably occurs and there are few 
long-term survivors, with a median overall survival (OS) from treatment of less than 2 
years. For this reason, eligible patients should be considered for consolidation therapies 
such as HSCT.  The results of alemtuzumab therapy compare favorably with outcomes 
reported with the use of purine analogues in which ORR are <50% and remission 
durations are less than one year.28-30 Single-agent pentostatin has shown the greatest 
efficacy of all purine analogues in T-PLL,28 although no randomized controlled trials 
have directly compared single agent pentostatin and alemtuzumab.  The use of 
pentostatin is discussed further in relapsed/refractory disease. Small prospective 
studies have evaluated the use of alemtuzumab in combination with chemotherapy 
agents.  For example, Hopfinger et al reported a prospective multi-center phase II trial 
investigating the use of fludarabine, mitoxantrone and cyclophosphamide (FMC) 
induction followed by alemtuzumab in 16 treatment-naïve patients and 9 previously-
treated patients.31 The ORR to FMC was 68% increasing to 92% following the addition 
of alemtuzumab. Median OS and PFS were 17.1 months and 11.9 months respectively. 
Alemtuzumab increases an individual’s susceptibility to opportunistic infections.  
Patients should therefore be on appropriate antibacterial and antiviral prophylaxis and 
undergo serology testing for cytomegalovirus (CMV), herpes simplex virus (HSV) and 
hepatitis B and C prior to commencement of treatment. In individuals who are 
seropositive for CMV prior to commencing alemtuzumab, serial CMV viral load should 
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be monitored for the early detection and management of CMV reactivation. Due to the 
risk of infertility with chemotherapy and HSCT, men and women should receive 
appropriate counselling and options for fertility preservation prior to commencing any 
treatment.  Intravenous administration of alemtuzumab is more effective than 
subcutaneous administration.32 Infusion reactions are common with alemtuzumab and 
measures should be employed to reduce the severity and occurrence of infusional 
reactions. One month following completion of therapy response to treatment should be 
measured by history, physical examination, full blood count, bone marrow aspirate and 
biopsy and computed tomography of the chest, abdomen and pelvis.  Response is 
defined using the criteria created for disease assessment in chronic lymphocytic 
leukemia (CLL).  
 
Post remission therapy 
Approximately 80% of patients achieve a CR following alemtuzumab treatment.  
However, without additional therapy, a majority of patients will relapse within two 
years.  HSCT is used to consolidate responses in eligible patients.  A number of studies 
have investigated the use of HSCT in T-PLL and suggest that OS can be improved and in 
a minority of cases can achieve a cure (Table 2).33-36 The main challenges to contend 
with are the treatment-related mortality (TRM) and risk of relapse.  A retrospective 
study by Guillaume et al reported 27 patients undergoing allogeneic HSCT (14 of who 
were in CR at time of HSCT).35 The relapse rate at 3 years was 47%, with a TRM of 31% 
and an OS of 36%.  The European Group for Blood and Marrow Transplantation (EBMT) 
registry had 41 patients with T-PLL who had received an allogeneic HCT.34 3 year OS 
was 21% with TRM and relapse rates of 41 percent (although nearly half of the patients 
had refractory disease at transplant time).  We reported a similar TRM rate and lower 3 
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year relapse rate from a smaller cohort of patients although a larger proportion of 
patients in our study were in CR, highlighting the importance of disease-status at time 
of HSCT.33  Although the number of patients is small, we also demonstrated similar OS 
in patients who received an autologous-SCT compared to those who received an 
allogenic-SCT.33    Although not offering a cure, given lower risk of treatment-related 
toxicity, autologous-SCT may be an option for less fit patients. Relapse following HSCT is 
usually within 2 years but can occur late. Given the increasing use of reduced-intensity 
conditioning and matched unrelated donors, as well as improvements in supportive 
care, more patients are eligible for HSCT, and the data which exists currently regarding 
HSCT may not be applicable to prospective cohorts of T-PLL patients. 
 
Therapy for relapsed and refractory disease 
Little data exists regarding the treatment of relapsed or refractory disease. 
Approximately half of the patients who relapse following a previous response to 
alemtuzumab can achieve a second disease remission with further alemtuzumab 
therapy, although this is usually of shorter duration.  Flow cytometry should be 
repeated as T-PLL cells can lose CD52 expression.  
 
Patients who fail to achieve a remission with single-agent alemtuzumab should have 
pentostatin added to the treatment regimen.   Although no randomized trials have 
compared single-agent therapy with combination therapy, pentostatin has 
demonstrated efficacy as a single-agent in a small retrospective study.  The ORR was 
45% independent of previous treatment with a median PFS and OS of 6 months and 9 
months respectively.28 A phase II study evaluated combination alemtuzumab with 
pentostatin in 13 patients with newly diagnosed or relapsed or refractory T-PLL. The 
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ORR was 69% with a median OS and PFS of 10.2 and 7.8 months, respectively.37 Despite 
adequate prophylaxis, common side effects included infection (including CMV 
reactivation) as well as neutropenia, thrombocytopenia, anemia and nausea.  
 
Other treatment options include nelarabine or bendamustine, although durable 
remissions with these therapies are uncommon.30 Herbaux et al report 15 patients with 
T-PLL treated with bendamustine, 7 of whom had failed front-line therapy with 
alemtuzumab. The ORR was 53% (20% CR), median PFS of 5 months and OS of 8.7 
months, independent of prior exposure to alemtuzumab.38 Treatment of patients with 
relapsed or refractory disease is currently suboptimal.  Effective novel therapies are 
needed to improve the outcome for these patients. 
 
Novel therapies 
New approaches aim to utilize our expanding knowledge of T-PLL in order to target 
pathways involved in disease pathogenesis and resistance. Given the high frequency of 
mutations observed, and the perturbed signaling pathways, small molecule inhibitors 
targeting JAK-STAT pathway represents a therapeutic strategy available for patients. 
Pimozide, a STAT5 inhibitor, has been shown to induce apoptosis in primary T-PLL 
cells.20 Histone-deacetlyase inhibitors (HDACi) in combination with hypomethylating 
agents aim to act synergistically to increase expression of silenced tumor suppressor 
genes.  The combination of cladribine and alemtuzumab with or without an HDACi can 
overcome alemtuzumab resistance and induce expression of other molecules liable to 
targeting with additional agents.39 Cells with inactive ATM demonstrate impaired DNA 
double strand break repair capabilities.  Poly (ADP-ribose) polymerase (PARP) 
inhibition imposes the requirement for DNA double strand break repair capabilities and 
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therefore selectively sensitize ATM-deficient tumor cells to killing.40 Finally, chimeric 
antigen receptor natural killer cells targeting CD7 may represent a novel therapeutic 
avenue not yet explored. 
 
SUMMARY 
T-PLL is a rare lymphoid malignancy with an aggressive clinical course and poor 
prognosis.  Careful evaluation of clinical features and laboratory tests is necessary to 
make an accurate diagnosis and ensure appropriate prognostication and treatment. 
Current therapy relies upon alemtuzumab followed by an HSCT in eligible patients 
achieving a CR.  In patients with relapsed or refractory disease, pentostatin can be 
added. Clinical outcomes are generally poor, although our increased understanding of 
the biology of T-PLL offers the promise of additional effective therapeutic options. 
  
  Sud et al 
 
 13 
REFERENCES 
1. Catovsky D, Galetto J, Okos A, Galton DA, Wiltshaw E, Stathopoulos G. 
Prolymphocytic leukaemia of B and T cell type. Lancet (London, England). 
1973;2(7823):232-234. 
2. Swerdlow S, Campo E, Harris N. World Health Organization Classification of 
Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2008. 
3. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features 
of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78(12):3269-3274. 
4. Bellone M, Svensson AM, Zaslav AL, et al. Pediatric T-cell prolymphocytic 
leukemia with an isolated 12(p13) deletion and aberrant CD117 expression. 
Experimental hematology & oncology. 2012;1(1):7. 
5. Mitton B, Coutre S, Willert J, et al. A pediatric case of T-cell prolymphocytic 
leukemia. Pediatric Blood & Cancer. 2015;62(6):1061-1062. 
6. Moser AM, Quider AA, Groen JA, Shubinsky G, Kapelushnik J. A gamma/delta T-
cell receptor prolymphocytic leukemia and CD4-/CD8- double-negative 
immunophenotype in a pediatric patient. Journal of pediatric 
hematology/oncology. 2015;37(4):e218-219. 
7. Suarez F, Mahlaoui N, Canioni D, et al. Incidence, Presentation, and Prognosis of 
Malignancies in Ataxia-Telangiectasia: A Report From the French National 
Registry of Primary Immune Deficiencies. Journal of Clinical Oncology. 
2015;33(2):202-208. 
8. Michallet AS, Lesca G, Radford-Weiss I, Delarue R, Varet B, Buzyn A. T-cell 
prolymphocytic leukemia with autoimmune manifestations in Nijmegen 
breakage syndrome. Annals of hematology. 2003;82(8):515-517. 
9. Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic 
lymphocytic leukemia: diagnosis and treatment. Mayo Clinic proceedings. 
2005;80(12):1660-1674. 
10. Magro CM, Morrison CD, Heerema N, Porcu P, Sroa N, Deng AC. T-cell 
prolymphocytic leukemia: an aggressive T cell malignancy with frequent 
cutaneous tropism. Journal of the American Academy of Dermatology. 
2006;55(3):467-477. 
11. Herling M, Valbuena JR, Jones D, Medeiros LJ. Skin involvement in T-cell 
prolymphocytic leukemia. Journal of the American Academy of Dermatology. 
2007;57(3):533-534. 
12. Song SX, Willemze R, Swerdlow SH, Kinney MC, Said JW. Mycosis Fungoides. 
Report of the 2011 Society for Hematopathology/European Association for 
Haematopathology Workshop. 2013;139(4):466-490. 
13. Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D. Abnormalities of 
chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by 
fluorescence in situ hybridization. Cancer genetics and cytogenetics. 
1998;103(2):110-116. 
14. Gritti C, Dastot H, Soulier J, et al. Transgenic Mice for MTCP1 Develop T-Cell 
Prolymphocytic Leukemia. Blood. 1998;92(2):368-373. 
15. Virgilio L, Lazzeri C, Bichi R, et al. Deregulated expression of TCL1 causes T cell 
leukemia in mice. Proceedings of the National Academy of Sciences. 
1998;95(7):3885-3889. 
16. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt 
kinase coactivator. Molecular cell. 2000;6(2):395-407. 
  Sud et al 
 
 14 
17. Costa D, Queralt R, Aymerich M, et al. High levels of chromosomal imbalances in 
typical and small-cell variants of T-cell prolymphocytic leukemia. Cancer 
Genetics. 2003;147(1):36-43. 
18. Soulier J, Pierron G, Vecchione D, et al. A complex pattern of recurrent 
chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes, 
chromosomes & cancer. 2001;31(3):248-254. 
19. Le Toriellec E, Despouy G, Pierron G, et al. Haploinsufficiency of CDKN1B 
contributes to leukemogenesis in T-cell prolymphocytic leukemia. Blood. 
2008;111(4):2321-2328. 
20. Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals 
mutational landscape of T-cell prolymphocytic leukemia. Blood. 
2014;124(9):1460-1472. 
21. Bellanger D, Jacquemin V, Chopin M, et al. Recurrent JAK1 and JAK3 somatic 
mutations in T-cell prolymphocytic leukemia. Leukemia. 2014;28(2):417-419. 
22. Lopez C, Bergmann AK, Paul U, et al. Genes encoding members of the JAK-STAT 
pathway or epigenetic regulators are recurrently mutated in T-cell 
prolymphocytic leukaemia. British journal of haematology. 2016;173(2):265-273. 
23. Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell 
receptor signaling define a hyperproliferative subset of T-cell prolymphocytic 
leukemia. Blood. 2008;111(1):328-337. 
24. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia 
with human CD52 antibody. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 1997;15(7):2667-2672. 
25. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic 
lymphoproliferative disorders. Cancer. 2003;98(4):773-778. 
26. Keating MJ, Cazin B, Coutré S, et al. Campath-1H Treatment of T-Cell 
Prolymphocytic Leukemia in Patients for Whom at Least One Prior 
Chemotherapy Regimen Has Failed. Journal of Clinical Oncology. 2002;20(1):205-
213. 
27. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell 
prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98(6):1721-1726. 
28. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of 
pentostatin in the treatment of T-cell malignancies: analysis of response rate in 
145 patients according to disease subtype. Journal of Clinical Oncology. 
1994;12(12):2588-2593. 
29. Kantarjian HM, Childs C, O'Brien S, et al. Efficacy of fludarabine, a new adenine 
nucleoside analogue, in patients with prolymphocytic leukemia and the 
prolymphocytoid variant of chronic lymphocytic leukemia. The American journal 
of medicine. 1991;90(2):223-228. 
30. Gandhi V, Tam C, O'Brien S, et al. Phase I Trial of Nelarabine in Indolent 
Leukemias. Journal of Clinical Oncology. 2008;26(7):1098-1105. 
31. Hopfinger G, Busch R, Pflug N, et al. Sequential chemoimmunotherapy of 
fludarabine, mitoxantrone, and cyclophosphamide induction followed by 
alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. 
Cancer. 2013;119(12):2258-2267. 
32. Dearden CE, Khot A, Else M, et al. Alemtuzumab therapy in T-cell prolymphocytic 
leukemia: comparing efficacy in a series treated intravenously and a study 
piloting the subcutaneous route. Blood. 2011;118(22):5799-5802. 
  Sud et al 
 
 15 
33. Krishnan B, Else M, Tjonnfjord GE, et al. Stem cell transplantation after 
alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than 
after alemtuzumab alone: a multicentre retrospective study. British journal of 
haematology. 2010;149(6):907-910. 
34. Wiktor-Jedrzejczak W, Dearden C, de Wreede L, et al. Hematopoietic stem cell 
transplantation in T-prolymphocytic leukemia: a retrospective study from the 
European Group for Blood and Marrow Transplantation and the Royal Marsden 
Consortium. Leukemia. 2012;26(5):972-976. 
35. Guillaume T, Beguin Y, Tabrizi R, et al. Allogeneic hematopoietic stem cell 
transplantation for T-prolymphocytic leukemia: a report from the French society 
for stem cell transplantation (SFGM-TC). European journal of haematology. 
2015;94(3):265-269. 
36. Kalaycio ME, Kukreja M, Woolfrey AE, et al. Allogeneic Hematopoietic Cell 
Transplant for Prolymphocytic Leukemia. Biology of Blood and Marrow 
Transplant. 2010;16(4):543-547. 
37. Ravandi F, Aribi A, O'Brien S, et al. Phase II Study of Alemtuzumab in 
Combination With Pentostatin in Patients With T-Cell Neoplasms. Journal of 
Clinical Oncology. 2009;27(32):5425-5430. 
38. Herbaux C, Genet P, Bouabdallah K, et al. Bendamustine is effective in T-Cell 
prolymphocytic leukaemia. British journal of haematology. 2015;168(6):916-919. 
39. Hasanali ZS, Saroya BS, Stuart A, et al. Epigenetic therapy overcomes treatment 
resistance in T-cell prolymphocytic leukemia. Science translational medicine. 
2015;7(293):293ra102-293ra102. 
40. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces 
significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. 
Blood. 2010;116(22):4578-4587. 
41. Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120(3):538-551. 
  Sud et al 
 
 16 
Table 1: Treatment Trials in T-PLL (> 10 patients) 
CR, complete remission; ORR, overall response rate; MPFS, median progression-free survival; MS, median overall survival; IV, intravenous; 
FMC, fludarabine, mitoxantrone and cyclophosphamide. 
 
  
Regimen  Number of patients CR ORR MPFS months MS months Reference 
Alemtuzumab (IV) 39 pre-treated 60% 76% 7  10  Dearden
41 
Alemtuzumab (IV) 32 untreated 81% 91%   Dearden
32
 
Bendamustine 9 pre-treated 
6 untreated 
 
20% 53.3% 5 8.7 Herbaux 
38 
FMC, then  
Alemtuzumab (IV) 
9 pre-treated 
16 untreated 
24% (FMC) 
48% (alemtuzumab) 
92% for all 25 
patients 
68% after FMC 
95% in 21 patients 
receiving 
alemtuzumab 
 
11.5   17.1 Hopfinger 
31 
Pentostatin + 
alemtuzumab (IV) 
13 (pre-treated + 
untreated)  
62% 69% 7.8 10.2 Ravandi 
37 
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Table 2: Allogeneic Stem Cell Transplant in T-PLL 
TRM, transplant related mortality; OS, overall survival; CR, complete remission; PR, partial remission. 
 
 
Number of 
patients 
Median age in 
years 
(range) 
Disease status at 
transplant  
TRM at 3 
years 
Relapse Rate at 3 
years  
Median OS 
(months) 
3 year OS Reference 
13 51 
(39-61) 
10 CR, 1PR 31% 33% 33 months 62% Krishnan 
33
 
41 51 
(24-71) 
11 CR, 12 PR 41% 41%  21% Wiktor-
Jedrzejczak
34
 
27 54 
(36-65) 
14 CR 31% 47%  36% Guillaume 
35
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Figure 1: Peripheral blood smear from a patient with T-prolymphocytic leukemia 
demonstrating a ‘typical’ morphology. 
The T-prolymphocytic leukemia cells are medium sized lymphoid cells with partial 
chromatin condensation and a visible nucleolus.  The cytoplasm is basophilic with 
protrusions and an absence of granules. 
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Figure 2: A pathway diagram illustrates the interaction of JAK1, JAK3, and STAT5B 
during cytokine activation. Cytokine binding results in JAK autophosphorylaton, 
leading to STAT recruitment and activation through tyrosine phosphorylation. 
Activated STAT proteins then dimerize and translocate to the nucleus to regulate 
transcription of numerous genes involved in differentiation, proliferation, and 
survival. Mutated components of the JAK1-JAK3-STAT5B pathway are highlighted. 
Mutations have also been described in IL2RG, which is a cytokine receptor. 
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